The cannabis industry really wants to give FDA more authority
The National Cannabis Industry Association, aka the weed lobby, is holding a congressional briefing this morning pushing their plan for streamlining the regulation of marijuana-based products. The plan is far reaching, covering everything from CBD lip balm to brownies that would make Jerry Garcia blush ... but there’s one common theme: Lots more responsibility for the FDA.
The plan would create four “lanes” for products to fit into: pharmaceutical drugs, like the CBD-based drug Epidiolex; ingestible or inhalable products with more than .3% THC, aka the products that will get you high; ingested or inhaled products with less than .3% THC, aka the ones that won’t get you high; and topical products that also don’t have much THC, aka products like your CBD bath bomb.
FDA would regulate the majority of these products, under the group’s plan -- with the exception of the products that get folks high, which would be primarily regulated by the Tobacco Tax and Trade Bureau of the U.S. Treasury, although FDA would still have a role establishing manufacturing standards for these products.
The plan would create four “lanes” for products to fit into: pharmaceutical drugs, like the CBD-based drug Epidiolex; ingestible or inhalable products with more than .3% THC, aka the products that will get you high; ingested or inhaled products with less than .3% THC, aka the ones that won’t get you high; and topical products that also don’t have much THC, aka products like your CBD bath bomb.
FDA would regulate the majority of these products, under the group’s plan -- with the exception of the products that get folks high, which would be primarily regulated by the Tobacco Tax and Trade Bureau of the U.S. Treasury, although FDA would still have a role establishing manufacturing standards for these products.
No hay comentarios:
Publicar un comentario